MDR-1-INHIBITION AND CYP3A ACTIVITY

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。我们的假设是，MDR 1活性可能影响ERBT，但不影响咪达唑仑清除率，因此混淆了ERBT对CYP 3A的评估。我们研究的目的是证明研究性MDR 1抑制剂tariquidar/XR-9576（Xenova Ltd.，UK）将影响ERBT，但不影响咪达唑仑的处置，这可能解释了这两种测定CYP 3A活性的试验之间的不同结果。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Our hypothesis is that MDR1 activity may affect the ERBT but not the midazolam clearance, and thus confound CYP3A assessment by the ERBT. The purpose of our study is to demonstrate that inhibition of MDR1 activity by the investigational MDR1 inhibitor tariquidar/XR-9576 (Xenova Ltd., UK) will affect the ERBT but not midazolam's disposition, possibly explaining the disparate results between these two assays for the determination of CYP3A activity.